University of Ottawa

Hoth Licenses VCU Research On Halting Spike Protein Binding Hoth Therapeutics Inc. announced on 20 May that it is licensing technology and related intellectual property developed at Virginia Common

Below is Scrip’s monthly roundup, including information from Strategic Transactions , of recent technology transfer agreements between companies and academic or other research institutions. First

by Norra MacReady and Mary Thompson Medical and technological developments since the 1970s have revolutionized the treatment of atherosclerosis and heart attacks. Thirty years ago, the average hospita

With the release of the REMATCH trial, Thoratec now enjoys a first mover advantage in the alternative-to-transplant market for VADs. But will being first give Thoratec an edge or merely pave the way f